Ossio, an Israeli medtech startup that develops orthopedic fixation technology announced today that it closed a $38.5 million Series C financing round led by Growth equity firm MVM Partners. In other good news for Ossio, the company its OSSIOfiber Compression Screw Portfolio has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for maintenance of alignment and fixation of bone fractures, comminuted fractures, fragments, osteotomies, arthrodesis and bone grafts of the upper extremity, fibula, knee, ankle and foot in the presence of appropriate brace and/or immobilization.
OSSIOfiber® is the first-of-its kind implant material to securely fixate and fully integrate into the native anatomy with nothing left behind.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Unlike other implants, OSSIOfiber® contains the same organic minerals found in bones themselves, but it’s stronger—it eventually becomes part of the bone, encouraging a return to full strength naturally without the risks and costs associated with permanent hardware.1
Founded in Israel in 2014, Ossio is an orthopedic medical device company that says its goal is to completely transform the orthopedic experience for physicians, patients, and payers. Ossio’s mission is to replace metal implants as the standard of care in the more than 10 billion dollar orthopedic fixation market (screws, pins, plates) with an intelligent bone regeneration technology. OSSIOfiber™ represents a breakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore mobility with nothing permanent left behind.
“We are incredibly proud of the innovation we’ve brought to the orthopedic fixation market with our OSSIOfiber® technology. As demonstrated in clinical studies, and as we currently see in real-time clinical practice, our proprietary strong and bio-integrative platform continues to successfully deliver,” said Brian Verrier, CEO, OSSIO. “The achievement of our 1,000th implant milestone, along with the recent FDA clearance for our Compression Screw Portfolio, further showcase our commitment to changing a 100- year-old standard-of-care in orthopedic fixation, transforming the patient experience and improving the overall healthcare economics of orthopedics.”
